Abstract
Metastatic breast cancer often metastasizes to bone. The purposes of the study were (1) to evaluate the use of 99mTc-MDP bone scintigraphy for detection of metastatic bone lesions, and (2) to determine the efficacy of zoledronic acid in mice with breast cancer bone metastasis. All tumor-bearing mice were analyzed with radionuclide bone scintigraphy, X-ray, and histological analysis. The metastatic bone tissue was also harvested and analyzed by western blotting and real-time qPCR. Interestingly, zoledronic acid significantly decreased both the tumor burden and the incidence of bone metastasis in mice. In addition, histomorphometric, stereological, and molecular biology analyses demonstrated that zoledronic acid may function to inhibit breast cancer cell growth in the bone microenvironment and regulate the function of osteoblasts and osteoclasts in tumor-bearing mice. Finally, the attenuation of breast cancer bone metastasis using zoledronic acid can be accurately characterized by 99mTc bone scintigraphy in mice.
Similar content being viewed by others
References
Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J (2012) Cancer incidence and mortality in China, 2007. Chin J Cancer Res 24:1–8
Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD et al (2008) Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst 100:1352–1360
Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD et al (2009) The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Cancer Netw Suppl 7:S1–S29
Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, et al (2010) NCCN clinical practice guidelines in oncology: multiple myeloma, 2010, v.2. Available at: http://www.24hmb.com/UpLoad/Editor/2010/1/4/2010010471312017.pdf
Luo KW, Ko CH, Yue GG, Lee MY, Siu WS, Lee JK et al (2013) Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models. Cancer Lett 339:42–48
Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR et al (2012) Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med 16:2186–2195
Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559–4567
Jeong J, Lee KS, Choi YK, Oh YJ, Lee HD (2011) Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells. J Korean Med Sci 26:1569–1575
Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T et al (2008) Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 274:271–278
Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V et al (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109–116
Hiraga T, Williams PJ, Mundy GR, Yoneda T (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418–4424
Yoneda T, Willams PJ, Hiraga T, Niewolna M, Nishimura R (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16:1486–1495
El-Abdaimi K, Ste-Marie LG, Papavasiliou V, Dion N, Cardinal PE, Huang D et al (2003) Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone. Int J Oncol 22:883–890
Even-Sapir E (2005) Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46:1356–1367
Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953
Padhani A, Husband J (1998) Bone metastases. In: Husband JES, Reznek RH (eds) Imaging in oncology oxford. Isis Medical Media Ltd, U.K., pp 765–787
Yang S, Dong Q, Yao M, Shi M, Ye J, Zhao L et al (2009) Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by 99mTc–MDP bone scintigraphy. Nucl Med Biol 36:313–321
Wu C, Sun Z, Ye Y, Han X, Song X, Liu S (2013) Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia 91:205–210
Chen M, Ye Y, Ji G, Liu J (2010) Hesperidin upregulates heme oxygenase–1 to attenuate hydrogen peroxide-induced cell damage in hepatic L02 cells. J Agric Food Chem 58:3330–3335
Mandal MN, Vasireddy V, Jablonski MM, Wang X, Heckenlively JR, Hughes BA et al (2006) Spatial and temporal expression of MFRP and its interaction with CTRP5. Invest Ophthalmol Vis Sci 47:5514–5521
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396–1405
Costa L (2007) Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 16:S16–S20
Gallo M, Luca AD, Lamura L, Normanno N (2012) Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 23:597–604
Niikura N, Liu J, Hayashi N, Palla S, Tokuda Y, Hortobagyi G et al (2012) Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 118:2039–2047
Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544
Acknowledgments
This research was supported by The National Natural Science Foundation of China (No. 30772811, No. 81102597 and No. 81173269), “Shu Guang” project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation (No. 08GG12) and Sponsored by Program of Shanghai Subject Chief Scientist (No. 10XD1404000).
Conflict of Interest
We have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, C., Yang, S., Sun, Z. et al. Characterization of the Attenuation of Breast Cancer Bone Metastasis in Mice by Zoledronic Acid Using 99mTc bone Scintigraphy. Pathol. Oncol. Res. 20, 747–754 (2014). https://doi.org/10.1007/s12253-014-9756-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-014-9756-z